--- title: "Celularity (CELU) news: delisting and convertible notes" url: "https://aibio.space/companies/celularity/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CELU delisting, convertible notes and Nasdaq notice news: Celularity gets Nasdaq notice on market value of listed securities, has until December 7, 2026." --- CELU Celularity Inc. NASDAQ · United States # Celularity (CELU) news CELU delisting, convertible notes and Nasdaq notice news Debt Financing · 2026-09-28 ## [Celularity sells $11.01 million of secured convertible notes in deal of up to $25.0 million](https://aibio.space/news/celularity-sells-11-01-million-secured-convertible-notes-deal-up-25-0/) Celularity sold about $11.01 million of notes that convert at $1.50 a share, with warrants for about 4,037,000 shares. A second tranche of up to $10.0 million is available at the buyers' election through September 30, 2027. ## Latest Celularity news 1. 2026-07-29 Listings [Celularity gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027 to comply](https://aibio.space/news/celularity-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/) Celularity (Nasdaq: CELU) was told on July 23, 2026 that its Class A common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its listing, the company says. 2. 2026-06-29 Debt Financing [Celularity takes $1,000,000 secured loan from Barach family trust](https://aibio.space/news/celularity-takes-1-000-000-secured-loan-barach-family-trust/) Celularity signed a $1,000,000 secured loan with the Philip & Daniele Barach Family Trust at 4.0%. The loan matures at the earlier of 30 days after closing or receipt of certain financing proceeds, and it rises to 18.0% after a default. 3. 2026-06-12 Listings [Celularity gets Nasdaq notice on market value of listed securities, has until December 7, 2026](https://aibio.space/news/celularity-gets-nasdaq-notice-market-value-listed-securities-has-until/) Nasdaq told Celularity on June 9, 2026 that its market value of listed securities was below the $35 million minimum for 30 consecutive business days. The notice does not delist the stock. 4. 2025-09-03 Listings [Celularity regains Nasdaq compliance after filing two late quarterly reports](https://aibio.space/news/celularity-regains-nasdaq-compliance-after-filing-two-late-quarterly/) Nasdaq told Celularity on September 2, 2025 that it complies with Listing Rule 5250(c)(1) again, after the company filed its Form 10-Q reports for the periods ended March 31 and June 30, 2025. 5. 2025-03-31 Distress [Celularity delays 2024 annual report, citing liquidity and staffing constraints](https://aibio.space/news/celularity-delays-2024-annual-report-citing-liquidity-staffing/) Celularity expects 2024 revenue of $54.2 million and a loss from operations of $37.3 million, figures it says are still under review. ## Celularity at a glance - **Ticker**: CELU - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $586,000 ### Related companies - [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) NASDAQ: CELZ - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [Valion Bio](https://aibio.space/companies/valion-bio/) NASDAQ: VBIO - [Bone Biologics](https://aibio.space/companies/bone-biologics/) NASDAQ: BBLG - [BioRestorative Therapies](https://aibio.space/companies/biorestorative-therapies/) NASDAQ: BRTX - [RenovoRx](https://aibio.space/companies/renovorx/) NASDAQ: RNXT - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA - [Citius Pharmaceuticals](https://aibio.space/companies/citius-pharmaceuticals/) NASDAQ: CTXR ### Also on NASDAQ - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) KLRS - [Kazia Therapeutics](https://aibio.space/companies/kazia-therapeutics/) KZIA - [Vaxcyte](https://aibio.space/companies/vaxcyte/) PCVX - [MacroGenics](https://aibio.space/companies/macrogenics/) MGNX - [Revolution Medicines](https://aibio.space/companies/revolution-medicines/) RVMD - [Apnimed](https://aibio.space/companies/apnimed/) APMD ## Celularity annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$26.6 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | [$54.2 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | | Research and development | [$15.0 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | [$17.4 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | | Net income (loss) | [-$91.7 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | [-$57.9 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | | Cash from operations | [-$13.3 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | [-$6.4 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | | Cash and equivalents | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1752828/000149315226047787/) | [$738,000](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $586,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Celularity Was Celularity delisted? Our latest story on this, dated Jun 12, 2026: "Celularity gets Nasdaq notice on market value of listed securities, has until December 7, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/celularity-gets-nasdaq-notice-market-value-listed-securities-has-until/). Has Celularity sold convertible notes? Our latest story on this, dated Sep 28, 2026: "Celularity sells $11.01 million of secured convertible notes in deal of up to $25.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/celularity-sells-11-01-million-secured-convertible-notes-deal-up-25-0/). Has Celularity received a Nasdaq deficiency notice? Our latest story on this, dated Jul 29, 2026: "Celularity gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027 to comply". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/celularity-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/). What is the ticker symbol of Celularity? Celularity Inc. trades under the ticker CELU on NASDAQ. Where is Celularity listed? Celularity Inc. is listed on NASDAQ. What is the SEC CIK of Celularity? The SEC Central Index Key (CIK) for Celularity Inc. is 1752828. Its filings are on SEC EDGAR. How many shares does Celularity have outstanding? 32,450,679 shares as of 2026-10-19, per the cover page of its 10-Q filed 2026-10-20. Which country or territory is Celularity listed under? Our directory records Celularity Inc. under United States. What does Celularity do? Our directory classifies Celularity Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Celularity? The ISIN recorded for Celularity Inc. is US1511902041. Does aibio.space cover Celularity? aibio.space lists Celularity Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Celularity incorporated? SEC records list its state or country of incorporation as DE. What was Celularity's revenue last year? $26.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Celularity profitable? Celularity Inc. reported a net loss of $91.7 million for the fiscal year ended Dec 31, 2025, and used $13.3 million of cash in operations, per its annual report to the SEC. How much does Celularity spend on research and development? $15.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Celularity Members talk about Celularity (CELU). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Celularity, newest first. Each line links the filing it comes from. 1. 2026-09-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226044421/form8-k.htm) 2. 2026-09-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226042495/form8-k.htm) 3. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226038318/formnt10-q.htm) 4. 2026-07-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226035193/form8-k.htm) 5. 2026-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226028519/form8-k.htm) 6. 2026-05-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226025646/form8-k.htm) 7. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226023840/formnt10-q.htm) 8. 2026-04-30 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226020424/form10-k.htm) 9. 2026-04-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.03,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226018220/ex99-1.htm) 10. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226014319/formnt10-k.htm) 11. 2026-03-10 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315226009471/ex99-1.htm) 12. 2025-12-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315225029033/ex99-1.htm) 13. 2025-10-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315225019839/form8-k.htm) 14. 2025-09-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000164117225026245/form8-k.htm) 15. 2025-08-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000164117225023231/form8-k.htm) 16. 2025-05-20 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000164117225011751/form8-k.htm) 17. 2025-05-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000164117225008104/form8-k.htm) 18. 2025-04-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000164117225005884/form8-k.htm) 19. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1752828/000164117225001823/formnt10-k.htm) 20. 2025-03-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315225011156/form8-k.htm) 21. 2025-02-18 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315225007097/form8-k.htm) 22. 2025-01-24 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315225003635/form8-k.htm) 23. 2024-11-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315224048082/form8-k.htm) 24. 2024-11-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1752828/000149315224046341/formnt10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CELU on TradingView](https://www.tradingview.com/symbols/NASDAQ-CELU/). ## SEC filings and registration - **SEC name**: Celularity Inc - **CIK**: 1752828 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CELU (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 170 PARK AVE, FLORHAM PARK, NJ, 07932 - **Phone**: (908) 768-2170 - **Shares outstanding**: 32,450,679 as of 2026-10-19 (10-Q filed 2026-10-20) - **Former names**: GX Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1752828/000149315226047787/form10-q.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1752828/000149315226044917/form8-k.htm) filed 2026-09-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1752828/000149315226044892/form10-q.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1752828/000149315226044421/form8-k.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1752828/000149315226042495/form8-k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1752828/000149315226036648/form8-k.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1752828/000149315226035193/form8-k.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1752828/000149315226031216/form8-k.htm) filed 2026-06-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001752828), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Celularity Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CELU, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Celularity Inc. - **Ticker**: CELU - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US1511902041 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CELU/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/celularity/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Celularity (CELU) news: delisting and convertible notes", 2026-10-31, https://aibio.space/companies/celularity/